A Swedish biotechnology company, Elypta, has recently been awarded an EU grant for the development of a new test for the diagnosis of renal cell carcinoma (RCC).
The grant of £2.4m will be used to run a clinical trial to validate Elypta’s technology as a tool for monitoring patients who have been treated for RCC and are at risk of recurrence by looking at samples of their blood and urine. Currently, there are no reliable methods for the early diagnosis of RCC.
Elypta’s method measures the concentration of molecules called glycosaminoglycans in blood and urine, and in previous studies the test showed an accuracy of 100%. Elypta hope to launch the test in 2022.